AR170 / Y-Biologics - LARVOL DELTA

Y-Biologics said on the 7th that it signed a contract manufacturing and development (CDMO) deal with China’s WuXi Biologics to develop new drugs using its next-generation triple-target immuno-oncology platform, “Multi-AbKine.“ (Chosun Biz) - "Y-Biologics is currently developing three pipelines in parallel based on the Multi-AbKine platform. Among them, 'AR170' is being prepared for submission of an investigational new drug (IND) application for global clinical trials, including in the United States, in the first half of 2027, and 'AR166' in the second half of 2027."

IND • Licensing / partnership • Oncology